We claim:

1. Use of an effective dose of masupirdine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia, wherein the effective dose of masupirdine or a pharmaceutically acceptable salt thereof is selected from 25 mg to 125 mg, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia.

2. The use of claim 1, wherein 25 mg to 50 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient.

3. The use of claim 1, wherein 50 mg to 100 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient.

4. The use of claim 1, wherein 25 mg, 50 mg, 75 mg, 100 mg or 125 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient.

5. The use of any one of claims 1 to 4, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

6. The use as claimed in claim 5, wherein the patient is to be administered an effective dose of masupirdine dimesylate monohydrate, wherein the effective dose of masupirdine dimesylate monohydrate is selected from 25 mg to 125 mg.

7. The use of claim 6, wherein 25 mg, 50 mg, 75 mg, 100 mg or 125 mg of masupirdine dimesylate monohydrate is to be administered to the patient.

8. The use as claimed in any one of claims 1 to 4, wherein the effective dose of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient in combination with donepezil or a pharmaceutically acceptable salt thereof and memantine or a pharmaceutically acceptable salt thereof.

9. Use of the effective dose of masupirdine or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 in the manufacture of a medicament for the treatment of agitation/aggression in a patient with Alzheimer's disease dementia.

10. Use of the effective dose of masupirdine or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 in the manufacture of a medicament for the treatment of delusions, hallucinations, or delusions and hallucinations in a patient with Alzheimer's disease dementia.

11. The use of claim 8, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

12. The use of claim 8, wherein the pharmaceutically acceptable salt of donepezil is hydrochloride.

13. The use of claim 8, wherein the pharmaceutically acceptable salt of memantine is hydrochloride.